Two Sigma Investments LP Sells 171,590 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

Two Sigma Investments LP lessened its position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 92.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,633 shares of the company's stock after selling 171,590 shares during the period. Two Sigma Investments LP owned 0.07% of Protara Therapeutics worth $72,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in TARA. HBK Investments L P purchased a new stake in shares of Protara Therapeutics during the fourth quarter worth $106,000. Dimensional Fund Advisors LP bought a new stake in shares of Protara Therapeutics during the 4th quarter valued at $111,000. Bailard Inc. purchased a new stake in Protara Therapeutics during the 4th quarter worth about $157,000. Commonwealth Equity Services LLC boosted its stake in Protara Therapeutics by 90.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock worth $195,000 after purchasing an additional 17,572 shares during the period. Finally, 683 Capital Management LLC bought a new position in Protara Therapeutics in the 4th quarter worth about $330,000. Hedge funds and other institutional investors own 38.13% of the company's stock.

Insider Transactions at Protara Therapeutics

In related news, insider Jacqueline Zummo sold 21,224 shares of the firm's stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the transaction, the insider now directly owns 98,861 shares of the company's stock, valued at approximately $447,840.33. This trade represents a 17.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 12.50% of the company's stock.

Protara Therapeutics Trading Down 3.5%

Shares of NASDAQ:TARA traded down $0.11 during trading on Tuesday, reaching $3.06. The company had a trading volume of 162,552 shares, compared to its average volume of 774,668. The company has a fifty day moving average of $3.46 and a two-hundred day moving average of $4.23. The stock has a market capitalization of $118.05 million, a P/E ratio of -1.78 and a beta of 1.34. Protara Therapeutics, Inc. has a 12 month low of $1.60 and a 12 month high of $10.48.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.18. As a group, equities research analysts predict that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Scotiabank began coverage on shares of Protara Therapeutics in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 target price on the stock. Cantor Fitzgerald assumed coverage on shares of Protara Therapeutics in a report on Friday, March 14th. They issued an "overweight" rating on the stock. HC Wainwright reiterated a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research report on Monday, April 28th. Lifesci Capital initiated coverage on Protara Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 target price for the company. Finally, Jones Trading upgraded Protara Therapeutics to a "strong-buy" rating and set a $21.00 target price on the stock in a research note on Thursday, May 22nd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $20.50.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.